MarketPulse

VTGN

3 articles
GlobeNewswire Inc.GlobeNewswire Inc.··The Schall Law Firm

Vistagen Investors Pursue Securities Fraud Claims Over Misleading Drug Trial Statements

Schall Law Firm seeks Vistagen investors in class action over alleged false statements regarding fasedienol drug candidate's Phase 3 trial prospects.
VTGNsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Vistagen Therapeutics Faces Securities Class Action Over Drug Trial Disclosure Allegations

Rosen Law Firm announces March 16, 2026 deadline for investors to join securities class action against Vistagen Therapeutics ($VTGN) over alleged misleading statements regarding fasedienol drug trial.
VTGNsecurities class actionmisleading statements
GlobeNewswire Inc.GlobeNewswire Inc.··The Schall Law Firm

Schall Law Firm Opens Class Action Against Vistagen Over PALISADE-2 Trial Disclosures

Schall Law Firm launches securities fraud class action against Vistagen for allegedly making misleading statements about fasedienol drug trial prospects, affecting investors from April 2024 to December 2025.
VTGNsecurities fraudclass action lawsuit